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In the aging brain, the correct balance of neural transmission and its regulation is of
particular significance, and neuropeptides have a significant role. Prolyl oligopeptidase
(PREP) is a protein highly expressed in brain, and evidence indicates that it is related
to aging and in neurodegenration. Although PREP is regarded as a peptidase, the
physiological substrates in the brain have not been defined, and after intense research,
the molecular mechanisms where this protein is involved have not been defined. We
propose that PREP functions as a regulator of other proteins though peptide gated direct
interaction. We speculate that, at least in some processes where PREP has shown to
be relevant, the peptidase activity is only a consequence of the interactions, and not the
main physiological activity.
Keywords: prolyl oligopeptidase, neuropeptides, aging neuroscience, neurodegeneration, proten-protein
interactions
INTRODUCTION
Processes leading to the brain aging are complex, and scarcely known. A popular current view
is that the housekeeping mechanisms in the cells get faulty and damage starts to accumulate,
leading eventually to cell degeneration. An increase of redox stress is important in aging, as are the
processes involved in the managing cellular waste, and the maintenance of homeostatic turnover of
biological molecules, especially of proteins. In fact, all regulatory mechanisms within cells, among
cell-cell communication and those for organ homeostasis are susceptible of aging (Knight, 2000).
In the brain, the correct balance and regulation of neural transmission are of particular significance,
and neuropeptides play a significant role.
Prolyl oligopeptidase, also known as post-proline cleaving enzyme or prolyl endopeptidase,
abbreviated PO, PE, PEP, or POP (here called PREP) was discovered on the early 70’s as an
oxytocin cleaving enzyme (Walter et al., 1971) and further described as a peptidase able to cleave
short peptides (<30 a.a.) with a high specific cleavage at the C-side of proline (Szeltner and
Polgar, 2008). A relevant role of PREP in the brain was proposed when a number of neuroactive
peptides were described to be its substrates. Early experiments indicated that PREP seemed to be
involved in learning and memory and studies on animal amnesia models showed PREP inhibitors
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to be beneficial but not in all experiments (reviewed in
García-Horsman et al., 2007; Männistö et al., 2007). On
the other hand, altered PREP activity levels in the brain of
neurodegenerative disease patients seemed to be associated with
dementia. Furthermore, indications that PREP expression in the
brain increases with age were reported (Rampon et al., 2000).
Accordingly, search and development of potent and specific
inhibitors boomed, several patents were filed, and pharmaceutical
companies started clinical trials with PREP inhibitors as memory
enhancers for senile- or neurodegeneration- associated dementia
(Männistö et al., 2007; Lambeir, 2011b). Despite the intense
research on the biological relevance of PREP inhibition, a
consensus has not been reached on the identity of the substrate
peptides, or on the specific molecular brain pathways where
PREP would be exerting its role (Lambeir, 2011b).
The evidence of protein-protein interactions of PREP with
α-tubulin, GAP-43, and α-synuclein, independent of peptidase
activity (Schulz et al., 2005; Di Daniel et al., 2009; Lambeir,
2011a), has led to the idea that PREP has not only a role in
cleaving off physiologically active peptides, but probably also in
modulating the function of protein partners.
In this perspective, we propose that the physiological role of
PREP results from its direct interaction with partner proteins,
which in turn is modulated by peptides and their hydrolysis.
We speculate that, at least in some processes where PREP has
shown to be relevant, the peptidase activity is a consequence of
the protein-protein interactions, and not themain activity. In this
paper, we only describe briefly some of the distinct research on
PREP in the brain, which we found relevant for this proposal.
We do not aim to comprehensively review the recent literature
on PREP, and fine studies dealing with peripheral actions of PREP
and its role inmetabolic-inflammatory diseases, including cancer,
are not discussed in this paper.
PREP EXPRESSION/REGULATION IN THE
BRAIN
In the healthy adult brain, PREP is expressed in the cytoplasm
of the neurons, at low or high level, with no specific preference
in terms of associations with neurotransmitter specific fibers
(Myöhänen et al., 2009). PREP levels are particularly high in
pyramidal neurons, especially those of the cortical layers II to
VI, or those composing the hippocampal CA1 layer. Neuronal
populations with hippocampal projections at indusuim griseum
and lateral septal area are enriched with PREP. Also, high levels
of PREP are present in cerebellar Purkinje cells (Myöhänen et al.,
2009). In healthy brain, glial cells are practically devoid of PREP.
It is worth noticing that there is not always a correlation
between the protein levels assayed by immunohistochemistry
with the PREP peptidase activity measured in enzymatic assays
on tissue homogenates (reviewed in Myöhänen et al., 2009).
Nevertheless, studies on rodents have shown that the levels of
PREP fluctuate in several areas of the brain during embryogenesis
and aging, being highest at birth and significantly decreasing
in the adult brain (Agirregoitia et al., 2007), but increased
again by old age (Rampon et al., 2000). Regulatory mechanisms
controlling PREP expression are not known. However, there
is evidence that PREP mRNA transcription is controlled by
retinoic acid, which support a role of PREP in development
(Moreno-Baylach et al., 2011). Furthermore, during neural
differentiation in vitro (Moreno-Baylach et al., 2008) and in
vivo (Hannula et al., 2011) PREP is localized within neuronal
nuclei of undifferentiated cells, or at early stages of prenatal
development. The localization is cytoplasmic in mature neurons,
mainly perinuclear and in interaction with cytoskeletal proteins
(Schulz et al., 2005). This, combined with the previous discovery
that PREP is involved in the regulation of the inositol turnover
in several systems (Williams et al., 1999; Schulz et al., 2002), led
to the conclusion that there were new intracellular functions of
PREP, not related with the extracellular neuropeptidemetabolism
(Schulz et al., 2005). On the other hand, PREP immunoreactivity
(Fukunari et al., 1994), and gene expression (Jiang et al., 2001)
have been reported increased in the brains of healthy senescent
mice. These findings indicate that PREP participates in age-
dependent processes.
In sick or lesioned brain, PREP expression has been shown
to be changed. In experimental neuroinflammation, PREP is
dramatically overexpressed in glial cells (Penttinen et al., 2011;
Tenorio-Laranga et al., 2015), and possibly secreted to the
extracellular space. PREP secretion from reactive microglia in
vitro, has been shown to be toxic to neurons in culture in
an inhibitory sensitive manner (Klegeris et al., 2008). On the
other hand, in post-mortem analysis of the brains from patients
with Alzheimer’s or Parkinson’s disease, PREP co-localized with
pathological plaque deposits (Hannula et al., 2013).
EFFECT OF PREP INHIBITORS IN
BEHAVIOR, MEMORY AND LEARNING
The effects of PREP inhibitors on learning andmemory have been
extensively studied (reviewed in Männistö et al., 2007; Lambeir,
2011b). JTP-4819 is the best studied PREP inhibitor in the animal
models of cognitive functions. It has improved memory in many
animalmodels (Toide et al., 1995, 1997; Shinoda et al., 1997, 1999;
Miyazaki et al., 1998), but the effects have rarely been robust
or dose-dependent. Another intensively studied PREP inhibitor
S-17092 has been even in clinical studies (Morain et al., 2002).
Obviously S-17092 has not been promising enough, since the
latest reports from the human studies date back to year 2007
(Morain et al., 2007). In the radial-armmaze, a very potent PREP
inhibitor, KYP-2047, have shown no effects in scopolamine-
treated old and young rats (Peltonen et al., 2010), but their
performances were age-dependent; KYP-2047 alone had effects
on motility, increasing it in young rats, but decreasing in older
ones. On the other hand, in the water maze test (Jalkanen et al.,
2007), KYP-2047, dose-dependently improved performance of
scopolamine-treated young rats but not in older animals.
It is fair to conclude that the role of PREP in improvement of
memory and learning is inconsistent and where an effect has been
observed, the underlying mechanisms have not been identified
(Männistö et al., 2007). A common theory to explain the role
of PREP in memory and learning has been the increase in the
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levels of cognition-enhancing neuropeptides, such as substance
P, TRH, and AVP, by PREP inhibition. However, this has been
more like an assumption than a proven fact. The effects of
PREP inhibitors on neuropeptide levels have been tested, but
the results have varied with the PREP inhibitor used, the length
of the treatment and the brain area studied (Männistö et al.,
2007). It has been speculated that there are many enzymes
participating in the neuropeptide metabolism that blocking one
enzyme, like PREP, may not be sufficient to increase the levels
of neuropeptides (Jalkanen et al., 2007). Therefore, there are
no strong experimental evidence supporting that PREP would
participate in cognitive, or other behavioral processes, through
neuropeptide metabolism.
In other experiments, lesioning the dopaminergic medial
forebrain bundle by 6-OHDA did not affect the activity or
expression of PREP in the striatum and PREP inhibitors had
no effect (Peltonen, 2012). However, the single i.p. treatment
with KYP-2047 decreased the levels of dopamine in the striatum
and increased the levels of dopamine metabolites in the VTA
(Myöhänen et al., 2007). A recent study, found changes in the
levels of phosphorylated dopamine transporter (DAT) in mice,
dependent on PREP levels of expression (Julku et al., 2016).
The data suggests that PREP modulates DAT internalization,
which in turn modifies extracellular dopamine levels. The
mechanism of this regulation is not known, but the study did
not investigate changes on any specific neuropeptide (Julku et al.,
2016).
BEHAVIOR OF PREP KNOCK-OUT MICE
Di Daniel et al. (2009) demonstrated a disturbed control of
growth cone and synaptic function in a full PREP knock out
mice. These mice were aggressive and hyperactive but no other
behavioral findings were reported. A gene trap (GT) mouse
with PREP significantly knocked down was reported by Warden
et al. (2009). Interestingly, this study reported a decrease on
α-melanocyte-stimulating hormone levels; opposite of what it
would have been predicted if this peptide was a substrate of
PREP. Also in this work, an evidence was found of disruption
of processes where vasopressin and oxytocin are involved, but no
evidence of changes of the levels of these peptides was reported.
Using the same GT strain, D’agostino et al. (2013), detected a
decrease of long term potentiation in GT animals consistent with
the spatial memory impairment in the Morris water maze test.
A more detailed behavioral phenotyping of the PREP deficiency
seems to affect mouse motor activity and anxiety-like behavior
(Höfling et al., 2016).
Other studies on PREP-KO mice showed association of
PREP and neuroplasticity modulation probably mediated by
inflammatory response where polysialylated-neural cell adhesion
molecule (PSA-NCAM) levels are altered in the brain (Höfling
et al., 2016). Recent findings, using PREP overexpressing
neuroblastoma cells, indicate that PREP is implicated in the
regulation of PS-NCAM, most probably by modulating the
proteases which normally degrade NCAM forms (Jaako et al.,
2016).
PREP IN PSYCHIATRIC DISORDERS
There are several reports describing fluctuations on PREP
levels in patients suffering from depression, anxiety and bipolar
disorder (for reviews see e.g., García-Horsman et al., 2007;
Lambeir, 2011b). However, no peptides, which would link PREP
with those disorders have been identified. The most notable
finding in this area is the opposite action of PREP and lithium, a
well-known mood stabilizer, showing that that PREP is involved
in the regulation of inositol signaling, interacting with some
of the enzymes which control the levels of neuronal inositol
(Williams et al., 1999; Harwood, 2011). Again, no peptide
substrate of PREP has been related to any of these findings.
This fact could be taken as an argument of ignorance. However,
in view that the search for these peptides has been actively
pursued, it also stimulates the thinking to other directions. A lack
of correlation between neuropeptide levels, behavior and PREP
inhibition, described above, adds fuel to the fire.
ENZYMATIC ACTIVITY
PREP has endopeptidase activity. It cleaves short peptides at the
carboxyl side of proline, with the exception of the prolyl-prolyl
bond. There are few cases where PREP cleaves (in vitro) after
alanine and cysteine, but with much lower efficiency (Polgar,
1992; Szeltner et al., 2002a; Bar et al., 2006).
There are many proline containing biologically active
peptides, often neuropeptides. Because proline is the only amino
acid with a secondary amine group, it confers special secondary
structure to peptides, and its presence in the peptide chain
confers resistance to degradation by most proteases. Thus, PREP
has been considered to be the specific hydrolyser of proline-
containing neuropeptides. In fact, any short proline-containing
peptide will be degraded by PREP in vitro, and indeed, there
are dozens of peptides reported to be substrates of PREP (for
reviews see García-Horsman et al., 2007; Brandt et al., 2007).
Table 1 summarizes the data on the few neuropeptides where
more extensive research has been conducted on relation to
PREP activity. In all, a validation of PREP being responsible
for the metabolism of those peptides in vivo has not been
conclusive. There have been fine efforts to identify the
physiological substrates of PREP in the brain, using sophisticated
mass spectrometric techniques on hypothesisless experimental
approaches (Brandt et al., 2005; Nolte et al., 2009; Tenorio-
Laranga et al., 2009, 2011, 2012; Lone et al., 2010). However,
the results have been scanty. These findings, combined with the
inconsistency of those obtained from in vivo behavioral data
described above, rise concern on the physiological relevance of
the peptidase activity of PREP.
Compared with other proteases, the enzymatic peptide
cleavage activity of PREP is relatively poor. Depending on the
peptide substrate, the turnover numbers of mammalian PREP are
around one per second, and the catalytic efficiencies are below 1
M−1 per second; the Km for substrates are in the order of 10−4
M or higher (METROPS the peptidase database, http://merops.
sanger.ac.uk/; Rawlings et al., 2016). At physiological conditions,
peptide concentrations are usually much below those levels,
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and then the cleavage of the peptides would be much slower.
Moreover, and to complicate the scenario, endogenous systems
which inhibit PREP have been identified (Tenorio-Laranga et al.,
2013). Thus, the peptide substrates would have to compete with
them to be efficiently hydrolysed by PREP. Notably, the levels of
protein expression of PREP seldom correlates with the activity
levels or with its mRNA levels. This strongly suggests that there
are processes controlling PREP’s transcription, translation, and
enzymatic activity, and the actual modulation in PREP protein
levels might not be meant to alter the peptidase activity. Finally,
PREP is a large protein if it is considered to have only the protease
activity.
PROTEIN-PROTEIN INTERACTIONS, PPIS
In earlier experiments, a particular intracellular distribution of
PREP was described (Rossner et al., 2005; Schulz et al., 2005),
which prompted to propose a role of PREP in protein secretion
and/or axonal transport within the neurons, probably through
tight interactions with structural proteins (Table 2). In fact, an
evidence of a direct interaction of PREP with α-tubulin was
found (Schulz et al., 2005). Consistent with this proposal, further
experiments with PREP-null mutations found altered growth
cone dynamics (Di Daniel et al., 2009). These alterations were
reversed in the PREP-null cells by virally expressed wild type
PREP. Surprisingly, a full reconstitution of activity was observed
also when the cells were transfected with a catalytically inactive
PREP mutant. That study also showed an interaction of PREP
with growth associated protein 43 (GAP-43), a regulator of neural
plasticity.
It has been reported that a POP inhibition suppressed
the mRNA levels of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), decreased age-induced apoptosis and also prevented
GAPDH nuclear translocation in cultured neurons (Katsube
et al., 1999). Effects on GAPDH translocation was also found
in fibroblasts (Puttonen et al., 2006). Another study described
physical interaction of PREP with GAPDH, and suggested that
this would modulate GAPDH translocation to the nucleus
TABLE 1 | Most researched peptides as substrates of PREP in the brain and the evidence in vivo and in vitro.
Evidence of physiological PREP digestion
Neuropeptide in vivo in vitro
Substance P (SP) Levels of SP, or peptide derivatives, in brain after in vivo PREP
inhibition, have been found changeda or unchangedb. Increase of SP
immunoreactivity levels after PREP inhibition in vivoc. No changes of
SP in rat striatum by in vivo microdialysisd. Potentiatione of SP activity.
SP degradation sensitive to specific PREP inhibitors in tissue
homogenatesf . Evidence that SP is degraded by fibroblast
activation protein αg. No immuno co-localization of PREP
with SP, or NK-1 receptorsh.
Thymosin β4 (TB4) TB4 fragments (Ac-SKDP) levels altered in whole animals
a. Inhibition of
Ac-SDKP action in whole animals by PREP inhibitioni.
Increase on Ac-SKDP release from TB4 uponi.
Thyrotropin releasing
hormone (TRH)
PREP inhibitors increase TRH immunoreactivity in some areas of the rat
brainj. PREP inhibitors did not changed effect of administrated TRHk.
Increased or unchanged TRH immunoreactivity upon PREP
inhibitorsl.
Gonadotropin releasing
hormone (GnRH)
No in vivo evidencel. PREP inhibitor sensitive in vitro degradation of GnRH in tissue
homogenatesl.
aNolte et al. (2009).
bTenorio-Laranga et al. (2009, 2012).
cBellemère et al. (2003).
dJalkanen et al. (2011).
eSchulz et al. (2002).
fSaidi et al. (2016).
gKeane et al. (2011).
hMyöhänen et al. (2008).
iMyöhänen et al. (2011).
jBellemère et al. (2005).
kLazcano et al. (2012).
lReviewed in García-Horsman et al. (2007).
TABLE 2 | Proteins that have protein interactions with PREP.
Protein Evidence References
α-tubulin Detected by two-hybrid screen. Immunohistochemical colocalization. Schulz et al., 2005
α-synuclein Inferred by α-synuclein anti-aggregation effect of PREP. Detected by
protein-fragment complementation assays and microscale thermophoresis
Van der Veken et al., 2012; Lambeir, 2011a; Savolainen et al., 2015
GAP-43 Interaction by yeast-two-hybrid, co-precipitation and ELISA assays Di Daniel et al., 2009; Szeltner et al., 2011
α-2-macroglobulin Co-purification Tenorio-Laranga et al., 2013
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during apoptosis in neuroblastoma cells (Matsuda et al.,
2013).
The most studied interaction of PREP is with α-synuclein
(Di Daniel et al., 2009), reviewed by Lambeir (2011a). Brandt
et al. (2008), found that PREP was able to interfere with the
aggregation process of α-synuclein in vitro. In those experiments,
it was relevant that the stimulation of the aggregation of α-
synuclein by PREP was not due to peptide cleavage, but it
was occurring independent of PREP activity by a process that
was anyhow sensitive to PREP inhibitors, since catalytically
inactive mutants of PREP showed same effect. The interaction
of PREP with α-synuclein aggregates was also observed in
cellular models and in in vivo mouse models over-expressing α-
synuclein (Myöhänen et al., 2012; Savolainen et al., 2014). The
mechanism of how PREP inhibitors are promoting α-synuclein
disaggregation is not known, but it certainly seems not to be due
to the inhibition of peptide cleavage activity of PREP. Rather it
happens by modulating PPIs with α-synuclein, or other partners,
probably in a chaperone-like process.
As mentioned, it has been proposed that PREP might be
involved in the protein secretion (Schulz et al., 2005; Morawski
et al., 2011). Indications that PREP participates in the secretion
of hormones that control glucose homeostasis have been reported
(Kim et al., 2014). Secretion, and protein clearance mechanisms
have been explored to try to define the process where PREP
inhibitors may be involved in decreasing α-synuclein aggregation
in the brain. The results indicate that PREP might be involved
in the control of autophagy (Savolainen et al., 2014), by still
unknown mechanisms, without indications of specific hydrolysis
of a peptide substrate of PREP.
PROTEIN STRUCTURE/MOLECULAR
MODELING
Structural information indicates that PREP has two distinctive
structural components (Figure 1): the protease catalytic domain,
with a classic α-β hydrolase fold (residues 1–71 and 436–710),
and a seven-bladed β-propeller domain (residues 72–435). When
the crystal structure of PREP was solved (Fülöp et al., 1998),
it seemed evident that the propeller domain might function as
a substrate gate. Very detailed kinetic studies supported this,
showing that the propeller may acts as a gating filter, allowing
the access of only short peptides to the active site (Fülöp et al.,
2000; Szeltner et al., 2000; Szeltner and Polgar, 2008). Molecular
dynamic studies have predicted an important role of the β-
propeller in substrate gating, but they also have shown that the
domain experience conformational changes that expose or hide
certain residues upon ligand binding (Kaushik and Sowdhamini,
2011; Kaszuba et al., 2012; Lopez et al., 2016; Van Elzen et al.,
2017). Further studies have indicated that PREP seems to exist
naturally in three conformations, with different catalytic and PPIs
features, in which the loops at the interface of both catalytic and
propeller domains are crucial components (Szeltner et al., 2011,
2013).
The β-propeller folding is present in a large variety of proteins,
and in most cases the function of this domain is to mediate PPIs
FIGURE 1 | 3-Dimentional model of porcine PREP based on its crystal
structure (Fülöp et al., 1998, 2001; Rea and Fülöp, 2011). The figure
shows the catalytic domain (α/β-hydrolase fold) and the propeller domain
(7-bladed β-propeller fold).
(Chen et al., 2011). Therefore, it is feasible to think that the main
function of this domain in PREP is to interact with large proteins.
Molecular dynamics of PREP has revealed that ligand binding
modifies the protein dynamics of the domain interface, probably
favoring one of the three conformations (Szeltner et al., 2011;
Kaszuba et al., 2012; Lopez et al., 2016).
All this information along with the fact that there have been
no definitive conclusions on “the substrates” of PREP, a different
hypothesis could be presented on the function of PREP. Shortly:
PREP interacts with a protein partners, and the strength of
the interaction will depend on the conformation of PREP. This
conformation will be in turn mainly dictated by the presence of a
ligand, a peptide, and the control of this switch will be mediated
by cleavage of the peptide (Figure 2).
In the Figure 2 we propose a scheme of this novel scenario.
PREP would interconvert among three basic conformations. The
closed form I is inactive and closed to ligand/peptide binding.
Stabilization of this form is caused at least by two factors. One
is the redox environment. It has been recognized that PREP
responds to redox conditions so that reductants activate the
enzyme (Szeltner et al., 2002b, 2003; Agustí-Cobos and Tenorio-
Laranga, 2011). Furthermore, redox conditions also change the
interaction with lipids and other partners (Tenorio-Laranga et al.,
2008; Szeltner et al., 2011, 2013). The second is an endogenous
inhibitor (Figure 2). Such inhibitors have indeed been described
in the literature (Soeda et al., 1986; Salers, 1994; Tenorio-Laranga
et al., 2010, 2013; Telford et al., 2011). The open, or active form
may exist in different species: form A is open when empty, and
the population of this species is probably very low, especially
when appropriated concentrations of the peptide substrate (S)
are present and tightly bound to PREP to produce the form
A-S. The A-S form may also be a very transient species since
it turns to the form A∗-S, which has a conformational change
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FIGURE 2 | A proposed functional cycle for PREP. PREP in an active form (A) can bind a substrate peptide (S) to become the form A-S. This form is
prone to produce a conformational change in PREP, depicted as a red area, becoming A*-S. This is a stable complex driving the equilibrium A to A-S to the formation
of A-S. The A*-S form, due to the particular conformation, is now able to interact with a protein partner (P) forming a tertiary complex A*-S-P, which is the biologically
active form. The tertiary complex A*-S-P can be broken by substrate cleavage, regenerating the form A, with low affinity by the partner P. The form active A can be
deactivated by interaction with an endogenous inhibitor (EI) or/and reactive oxidative species (ROS). The form A*-S could slowly lead to substrate cleavage.
around the propeller region, induced by the ligand (substrate or
inhibitor) binding. Conformational changes in this domain, upon
ligand binding, have been demonstrated (Szeltner et al., 2000,
2004; Kiss et al., 2004). We suggest that the form A∗-S is able
to interact with a PPI partner (P in Figure 2), and subsequently
form a stable tertiary complex, the form A∗-S-P. This form may
have a particular biological activity which prevails as long as it
is stable. Its stability may be broken by the hydrolysis of the
peptide by PREP. PREP inhibitors may have different activities.
One may stabilize the PPI active forms of PREP (A∗-S, and in
turn also A∗-S-P), or stabilize the form A-S, which is not able to
interact with the PPI partner. Fine kinetic studies have indicated
that PREP inhibitors show a complex kinetics, and allosteric-like
interaction have been proposed (Fülöp et al., 2001; Szeltner et al.,
2004; Fuxreiter et al., 2005; Juhasz et al., 2005). In the absence
of a PPI partner, e.g., in vitro, the cycle could short circuit from
form A∗-S (or A-S) to form A, through a catalytic cleavage by
peptidase, but this is predicted to be a slow process. The relative
low activity of PREP in vitro, compared with other peptidases,
support this notion. In fact, despite appreciable amounts detected
in circulation, some researchers are not able to detect any activity
at all (Lee et al., 2011). In this cycle, we would like to point that
it is the formation of a complex PREP-Partner (form A∗-S-P)
whichmight be physiologically relevant, and peptide binding and
cleavage, are only regulatory factors.
It is interesting to note that PREP-like protein (PREPL),
a member of prolyl oligopeptidase family, has a structure
highly homologous to PREP (Szeltner et al., 2005) including a
β-propeller and a catalytic domain. Even if PREPL is catalytically
active, no peptides/proteins have been found to be cleaved by
it, in spite of the great efforts to find them (Martens et al.,
2006; Boonen et al., 2011). PREPL deletion produces severe
growth impairment (Lone et al., 2014), and indeed it has been
speculated that its function is to interact with other proteins
important in growth, in a similar fashion to PREP (Boonen et al.,
2011), probably through a mechanism here proposed. In fact, the
intracellular localizations of PREPL and PREP are very similar
(Morawski et al., 2013), which has led to the suggestion that
both proteins have a redundant function. On the other hand,
similar PPI function mechanism could be speculated for two
enzymatically inactive dipeptidyl peptidases DPP6 and DPP10.
Although structurally less homologous to PREP than PREPL,
they are implicated in a number of neuronal processes in health
and disease (McNicholas et al., 2009), and ligands (peptides?)
may be proposed to regulate their PPI activities even in the
absence of an active center.
CONCLUSIONS
PREP has been implicated in several of brain processes, like
memory, learning, secretion, plasticity, and aging. Since PREP
has an enzymatic activity for cleaving short peptides, it has been
logically related in regulation of the neuropeptide levels (García-
Horsman et al., 2007; Männistö et al., 2007; Lambeir, 2011b).
However, extensive research has not been able to definitively
identify the physiological substrate peptides. Potent and selective
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PREP inhibitors have not robustly elevated the putative substrate
levels, and even inactive PREP mutants have retained some
functions, suggesting that peptidase activity is evidently not
always required for some of the processes where PREP has been
associated to. We here propose that rather than the peptidase
activity, it is the direct PREP-other protein interaction that is
primarily involved in the several processes mentioned (Figure 2).
We suggest that PREP regulates through this interaction the
activity of other proteins such as proteases, transport proteins
and chaperones, according to the biological conditions and type
of the cell in question, and according to the prevalent peptide
homeostasis. Enzymatic activity of PREP may act only as a
regulator of its interactions with other proteins.
Aging is a complicated process where both genes and
environment play key roles and interact.
However, the mechanisms of how these factors influence
longevity is still not understood. There is some evidence that
cellular systems of housekeeping, repair and stress responses
are crucial. Regulation of these processes is still mostly
unknown. New hypothesis may be a useful starting point to fill
the gaps.
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